
Opinion|Videos|August 9, 2024
Linking Type 2 Inflammation to Asthma and COPD
Author(s)Reynold A. Panettieri Jr, MD
A key opinion leader examines the etiology of asthma and potential risk factors for COPD development, emphasizing the role of environmental exposures.
Advertisement
Episodes in this series

- Describe type 2 inflammation and how it relates to asthma and COPD. How often is type 2 inflammation the cause of these diseases?
- How do environmental factors influence type 2 inflammation in respiratory diseases? Are there preventative measures patients can take?
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.
Advertisement
Advertisement



